[Federal Register Volume 67, Number 49 (Wednesday, March 13, 2002)]
[Notices]
[Page 11294]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-6019]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Navy


Notice of Availability of Government-Owned Invention; Available 
for Licensing

AGENCY: Department of the Navy, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of the Navy hereby gives notice of the general 
availability of exclusive or partially exclusive licenses under the 
following pending patent. Any license granted shall comply with 35 
U.S.C. 209 and 37 CFR part 404. Applications will be evaluated 
utilizing the following criteria: (1) Ability to manufacture and market 
the technology; (2) manufacturing and marketing ability; (3) time 
required to bring technology to market and production rate; (4) 
royalties; (5) technical capabilities; and (6) small business status.
    Patent application Serial Number 10/060605 entitled ``Rapid and 
Non-Invasive Method to Evaluate Immunization Status of a Patient'' 
filed January 30, 2002. The present invention relates to an assay 
method and kit for detecting the presence of a pre-designated, target 
IgG antibody in a sample selected from one or more patient bodily 
fluids. The method comprises the following steps: (a) Contacting the 
sample of one or more patient bodily fluids with a membrane-bound 
recombinant protective antigen to bind to the target IgG antibody in 
the sample; (b) previously, simultaneously or subsequently to step a., 
binding the protective antigen (PA) with a conjugated label producing a 
detectable signal; and (c) detecting the signal whereby the presence of 
the target IgG antibody is determined in the sample by the intensity of 
the signal. The method can further comprise the step of evaluating 
immunization status of the patient from whom the sample came by 
comparing the signal or lack thereof with immunizations previously 
received by the patient. In a preferred embodiment, the recombinant 
protective antigen (PA) specifically binds to anthrax protective 
antigen-specific IgG antibodies. Preferably, the immunoassay of the 
present invention comprises a lateral-flow assay comprising a membrane, 
a conjugated label pad, and a recombinant protective antigen (PA) bound 
to the membrane.

DATES: Applications for an exclusive or partially exclusive license may 
be submitted at any time from the date of this notice.

ADDRESSES: Submit applications to the Office of Technology Transfer, 
Naval Medical Research Center, 503 Robert Grant Ave., Silver Spring, MD 
20910-7500, telephone (301) 319-7428.

FOR FURTHER INFORMATION CONTACT: Dr. Charles Schlagel, Director, Office 
of Technology Transfer, Naval Medical Research Center, 503 Robert Grant 
Ave., Silver Spring, MD 20910-7500, telephone (301) 319-7428 or e-mail 
at [email protected].

    Dated: March 6, 2002.
T.J. Welsh,
Lieutenant Commander, Judge Advocate General's Corps, U.S. Navy, 
Federal Register Liaison Officer.
[FR Doc. 02-6019 Filed 3-12-02; 8:45 am]
BILLING CODE 3810-FF-P